Author

Florentia; https://orcid.org/0000-0003-4529-3372 Dimitriou

Observed names: Dimitriou, F., Dimitriou, Florentia, Dimitriou, Florentia; https://orcid.org/0000-0003-4529-3372, Florentia Dimitriou

Observed institutions: University of Zurich, University Hospital Zurich

ORCID: 0000-0003-4529-3372

Observed ORCID: 0000-0003-4529-3372

OpenAlex ID: A5151001306

A targetable type III immune response with increase of IL-17A expressing CD4$^{+}$ T cells is associated with immunotherapy-induced toxicity in melanoma

2024 · Dimitriou, Florentia; https://orcid.org/0000-0003-4529-3372, Cheng, Phil F; https://orcid.org/0000-0003-2940-006X, et al. · Zurich Open Repository and Archive (University of Zurich) · 2

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

2025 · Dimitriou, F., Orloff, M.M., et al. · Leiden Repository (Leiden University) · 1

PDF

Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy

2024 · Woodford, R., McKeown, J., et al. · Leiden Repository (Leiden University) · 1

PDF

Efficacy and safety of ‘Second Adjuvant’ therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

2024 · Taylor, Amelia M, McKeown, Janet, et al. · Zurich Open Repository and Archive (University of Zurich)

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

2024 · Jacques, Sarah K, McKeown, Janet, et al. · Zurich Open Repository and Archive (University of Zurich)

Works count: 10

Citation count: 4

H-index: 1

I10-index: